Active Research Studies: Lymphoma
Comprehensive Cancer Centers is currently running the following Phase II and Phase III clinical research studies for lymphoma:
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies **OPEN TO COHORTS 1- CLL AND SLL AND COHORT 2- MCL. ON HOLD- COHORTS 3-7**
Study#: i3217
Contact Us: For information about this clinical study, Email Us.
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)
Study#: i3285
Contact Us: For information about this clinical study, Email Us.
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor
Study#: i3320
Contact Us: For information about this clinical study, Email Us.
Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib with Different Ramp- Up Periods in Previously Untreated Subjects with CLL
Study#: Independent/Lymphoma
Contact Us: For information about this clinical study, Email Us.